Oculus imaging device approved by FDA

Article

The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.

The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.

The slim, ergonomically-designed device features a 5.7" LCD display, and comprises an autorefractor combined with a Scheimpflug based non-contact pachymeter, to photograph and measure corneal thickness and lens refractive power. It can be set to PARK, ARK or P measurement modes.

The PARK 1 will be launched officially at this year's American Academy of Ophthalmology (AAO) meeting, which is to be held on November 8–11 in Atlanta, GA, US.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
© 2025 MJH Life Sciences

All rights reserved.